Diag-Nose.io
Melbourne
About Diag-Nose.io
Diag-Nose.io, founded in 2020 is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions. Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies. The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $5.2M
- Funding stage: Seed
- Last round: Grant (Aug 2025)
- Website: diag-nose.io
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/diag-nose-io-110227 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.